Genentech’s Enspryng (Satralizumab) Cuts Relapse Risk by 68%, Showing Promise as a Potential First Treatment for MOGAD
Genentech, a member of the Roche Group, has announced compelling new results from its Phase III METEOROID clinical trial evaluating Enspryng (satralizumab) in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a rare and often disabling autoimmune neurological disorder. The findings demonstrate a statistically significant and clinically meaningful reduction in relapse risk, marking a potential turning point in the treatment landscape for this underserved patient population.
The results, presented during a late-breaking oral session at the American Academy of Neurology Annual Meeting 2026 in Chicago, showed that Enspryng reduced the risk of relapse by 68% compared with placebo. The study successfully met its primary endpoint, which measured the time from randomization to the first confirmed relapse during the double-blind treatment period. The outcome was statistically significant, with a p-value of 0.0025, underscoring the robustness of the findings.
MOGAD is a rare autoimmune condition characterized by inflammation of the central nervous system, often affecting the optic nerves, brain, and spinal cord. The disease can lead to recurrent relapses that result in cumulative neurological damage, including vision loss, motor impairment, and long-term disability. Despite its severity, there are currently no approved therapies specifically indicated for MOGAD, leaving clinicians to rely on off-label immunosuppressive treatments with variable efficacy.
According to Michael Levy, an associate professor at Harvard Medical School and physician at Massachusetts General Hospital, the results from the METEOROID study represent a significant breakthrough. He emphasized that MOGAD patients face unpredictable disease activity, with relapses that can cause irreversible neurological injury. The ability of Enspryng to demonstrate meaningful clinical benefit in a pivotal trial offers new hope for patients who have long lacked targeted treatment options.
The primary endpoint analysis revealed that 87% of patients receiving Enspryng remained relapse-free at 48 weeks, compared to 67% of those receiving placebo. Notably, the onset of treatment effect was observed as early as eight weeks after initiation, suggesting a relatively rapid therapeutic impact. The benefit of Enspryng was consistent across multiple patient subgroups, including differences in age, sex, race, and use of background therapies, indicating broad applicability across diverse patient populations.
In addition to the primary endpoint, the study also met key secondary endpoints that further reinforce the clinical value of Enspryng in MOGAD. One such endpoint was the annualized relapse rate (ARR), which was reduced by 66% in patients treated with Enspryng compared to placebo (p=0.0030). Given that disability progression in MOGAD is closely linked to relapse frequency and severity, reducing ARR is a critical therapeutic objective.
Beyond relapse prevention, the METEOROID study also demonstrated significant effects on markers of central nervous system (CNS) inflammation. Imaging data showed a 79% reduction in the annualized rate of active lesions detected by MRI across key regions, including the optic nerves, brain, and spinal cord. This finding suggests that Enspryng not only reduces clinical relapses but may also address underlying inflammatory processes that drive disease progression.
Another important outcome was the reduction in the need for rescue therapies. Patients treated with Enspryng experienced a 73% lower likelihood of requiring interventions such as corticosteroids, plasma exchange, or intravenous immunoglobulins compared to those on placebo. These therapies are typically used to manage acute relapses and can be associated with significant side effects and healthcare resource utilization. Therefore, reducing their use represents both a clinical and economic benefit.
While not statistically significant, the study also observed a numerical 17% reduction in the annualized rate of inpatient hospitalizations among patients receiving Enspryng compared to placebo. Although the p-value for this endpoint did not reach significance, the trend suggests a potential impact on healthcare utilization that may warrant further investigation in larger or longer-term studies.
From a safety perspective, Enspryng demonstrated a profile consistent with its established use in another neurological condition, aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD). No new safety signals were identified in the METEOROID trial, and the overall tolerability was in line with previous clinical and post-marketing experience accumulated over more than a decade.
The most commonly reported adverse events in patients receiving Enspryng, occurring in at least 5% of participants and more frequently than in the placebo group, included injection-related reactions (16%), influenza (9%), arthralgia (9%), back pain (9%), sinusitis (7%), and diarrhea (6%). Importantly, the rates of adverse events leading to temporary treatment interruption were low and comparable between the Enspryng and placebo groups, at 6% and 5%, respectively.
There was one reported fatality during the study; however, investigators determined that it was not related to the treatment. Additionally, none of the serious adverse events observed in the trial were considered to be treatment-related, further supporting the favorable safety profile of the therapy.
Levi Garraway, Chief Medical Officer and Head of Global Product Development at Genentech, highlighted the broader implications of the METEOROID findings. He described the 68% reduction in relapse risk as a remarkable achievement that could redefine the standard of care for MOGAD. According to Garraway, the results not only represent a scientific milestone but also reflect the company’s commitment to addressing diseases with high unmet medical need through targeted, mechanism-based therapies.
Enspryng is a monoclonal antibody designed to inhibit the interleukin-6 (IL-6) receptor, a key pathway involved in inflammatory and autoimmune processes. By blocking IL-6 signaling, the drug aims to reduce immune-mediated damage within the central nervous system. Its mechanism of action has already been validated in NMOSD, a related autoimmune condition, and the METEOROID data suggest that similar biological pathways may be relevant in MOGAD.
The success of the METEOROID trial is particularly significant given the challenges associated with studying rare diseases. Patient populations are often small and geographically dispersed, making it difficult to conduct large-scale randomized trials. Despite these challenges, the study was able to generate high-quality evidence supporting the efficacy and safety of Enspryng, providing a strong foundation for regulatory submissions.
Genentech has confirmed that the METEOROID data will be submitted to regulatory authorities worldwide, with the goal of securing approval for Enspryng as a treatment for MOGAD. If approved, it would become the first therapy specifically indicated for this condition, addressing a critical gap in the current treatment landscape.
The potential approval of Enspryng for MOGAD could also have broader implications for the field of neuroimmunology. It reinforces the importance of understanding disease-specific mechanisms and developing targeted therapies that go beyond generalized immunosuppression. As research continues to uncover the molecular drivers of autoimmune neurological disorders, similar approaches may lead to new treatments for other rare and complex conditions.
For patients and clinicians, the findings from the METEOROID study offer a renewed sense of optimism. The ability to significantly reduce relapse risk, limit CNS inflammation, and decrease reliance on rescue therapies represents a meaningful advancement in disease management. Moreover, the favorable safety profile supports the potential for long-term use, which is essential in chronic conditions like MOGAD.
In summary, the Phase III METEOROID trial results position Enspryng as a promising and potentially transformative therapy for myelin oligodendrocyte glycoprotein antibody-associated disease. With strong efficacy data, a well-characterized safety profile, and ongoing regulatory engagement, the therapy stands poised to become the first approved treatment for this debilitating condition. As the global regulatory review process moves forward, the MOGAD community will be watching closely, hopeful that a long-awaited therapeutic breakthrough is finally within reach.
About the METEOROID study
METEOROID is a Phase III, randomized, double-blind, placebo-controlled, multicenter study of Enspryng® (satralizumab) in adults and adolescents 12 years and older with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Eligible participants were randomized 1:1 to receive treatment with either Enspryng (60 mg, 120 mg or 180 mg based on body weight) or placebo, administered subcutaneously at 0, 2 and 4 weeks, then every 4 weeks thereafter.
Patients continued background immunosuppressant therapy if they were on treatment at randomization. The double-blind period was event-driven and ended after 28 adjudicated MOGAD relapses had been observed. Patients who experienced an adjudicated relapse or completed the double-blind period have the option to enter an open-label extension (OLE) period, in which all patients receive treatment with Enspryng.
The primary endpoint is the time from randomization to the first MOGAD relapse during the double-blind treatment period, as determined by an independent clinical adjudication committee. Secondary endpoints include the annualized rate of MOGAD relapses, the annualized rate of active lesions on MRI across the optic nerves, brain and spinal cord and the proportion of patients receiving rescue therapy (including oral or intravenous steroids, plasma exchange or intravenous immunoglobulins) and the annualized rate of inpatient hospitalizations.
About Enspryng® (satralizumab)
Enspryng, which was developed by Chugai, a member of the Roche Group, is a humanized monoclonal antibody that targets interleukin-6 (IL-6) receptor activity. Enspryng was designed using novel recycling antibody technology which, compared to conventional technology, allows for sustained IL-6 inhibition.
People with MOGAD have elevated levels of IL-6 in cerebrospinal fluid (CSF) and serum, which promote T-cell-mediated inflammation, stimulate autoantibody production from plasma cells and disrupt the blood-brain barrier. By blocking IL-6 signaling, Enspryng has the potential to lower disease-related antibody production, suppress inflammatory T cells and restore the integrity of the blood-brain barrier.
Enspryng is the first and only IL-6 inhibitor treatment currently approved in approximately 90 countries for AQP4-IgG seropositive NMOSD, with more than 9,000 patients treated. Enspryng offers the flexibility of at-home self-administration with subcutaneous injections, following training and approval from a healthcare provider. At initiation, a loading dose of Enspryng 120 mg is administered every other week for a total of three injections. Maintenance doses are administered thereafter once every four weeks.
Genentech is committed to developing Enspryng in additional, neurological autoimmune and inflammatory diseases that may benefit from inhibition of IL-6 signaling, including autoimmune encephalitis (AIE) and thyroid eye disease (TED). The U.S. Food and Drug Administration (FDA) has designated Enspryng as an investigational orphan drug for MOGAD and anti-NMDA receptor autoimmune encephalitis (anti-NMDAR AIE). Genentech recently announced positive Phase III results for Enspryng in TED, with regulatory submissions planned this year.
About myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
MOGAD is a rare autoimmune disease of the central nervous system (CNS) that preferentially affects the optic nerves but can also affect the brain and spinal cord. The prevalence of MOGAD is estimated to range from 0.51 to 3.42 per 100,000 people. The disease can affect people of all ages, and the symptoms are often severe and debilitating, including loss of vision, pain, fatigue, numbness, bladder/bowel or erectile dysfunction, impaired ambulation and cognitive dysfunction. Relapsing MOGAD is characterized by multiple, unpredictable attacks of worsening neurological symptoms. Symptoms may not fully resolve after an attack, leading to accumulating, permanent, neurological damage, vision loss and disability.
Currently, there are no approved treatment options available for MOGAD.
About Genentech in neurology
Neurology is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new diagnostics and treatments that help improve the lives of people with chronic and potentially devastating diseases.
Genentech and Roche are investigating more than a dozen medicines for neurological conditions, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neurology today.
About Genentech
Founded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.
Source Link:https://www.businesswire.com/
